SG Americas Securities LLC Lowers Stake in Agios Pharmaceuticals Inc (AGIO)
SG Americas Securities LLC lowered its stake in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 55.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,432 shares of the biopharmaceutical company’s stock after selling 4,193 shares during the period. SG Americas Securities LLC’s holdings in Agios Pharmaceuticals were worth $196,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of AGIO. State of Alaska Department of Revenue bought a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $160,000. Teacher Retirement System of Texas bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter valued at $225,000. S&CO Inc. bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter valued at $227,000. Cubist Systematic Strategies LLC grew its holdings in shares of Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 3,123 shares during the last quarter. Finally, Bank of Montreal Can grew its holdings in shares of Agios Pharmaceuticals by 74.8% during the 4th quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 1,520 shares during the last quarter. Hedge funds and other institutional investors own 81.82% of the company’s stock.
In other Agios Pharmaceuticals news, insider Carman Alenson sold 2,150 shares of the firm’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $75.00, for a total value of $161,250.00. Following the sale, the insider now owns 2,150 shares of the company’s stock, valued at approximately $161,250. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Steven L. Hoerter sold 2,050 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $78.63, for a total transaction of $161,191.50. Following the completion of the sale, the insider now directly owns 2,050 shares in the company, valued at approximately $161,191.50. The disclosure for this sale can be found here. In the last three months, insiders sold 179,018 shares of company stock worth $13,682,761. Insiders own 5.43% of the company’s stock.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.16). The firm had revenue of $9.80 million during the quarter, compared to the consensus estimate of $12.65 million. Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. Agios Pharmaceuticals’s revenue was down 56.7% on a year-over-year basis. During the same period last year, the business earned ($1.34) EPS. equities analysts predict that Agios Pharmaceuticals Inc will post -6.15 earnings per share for the current fiscal year.
AGIO has been the topic of several recent research reports. Oppenheimer reaffirmed a “buy” rating and set a $83.00 target price on shares of Agios Pharmaceuticals in a report on Monday, December 11th. Cann reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. Canaccord Genuity set a $90.00 target price on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 12th. BidaskClub lowered shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 16th. Finally, Royal Bank of Canada increased their target price on shares of Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a report on Thursday, January 18th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $85.50.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.